| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Enterobacteriaceae Infections | 5 | 2019 | 529 | 0.87 | Why? |
| Influenza Vaccines | 12 | 2020 | 2941 | 0.86 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 3 | 2019 | 214 | 0.85 | Why? |
| Pneumococcal Infections | 8 | 2019 | 562 | 0.84 | Why? |
| Post-Exposure Prophylaxis | 2 | 2021 | 472 | 0.76 | Why? |
| Streptococcus pneumoniae | 6 | 2019 | 827 | 0.73 | Why? |
| Urine | 2 | 2018 | 469 | 0.59 | Why? |
| Bacteriological Techniques | 1 | 2017 | 239 | 0.55 | Why? |
| Influenza, Human | 17 | 2020 | 10779 | 0.54 | Why? |
| Ontario | 19 | 2021 | 1966 | 0.49 | Why? |
| Cross Infection | 14 | 2019 | 8675 | 0.48 | Why? |
| Klebsiella Infections | 1 | 2017 | 466 | 0.48 | Why? |
| Microbiological Techniques | 1 | 2014 | 232 | 0.46 | Why? |
| Bacteremia | 4 | 2018 | 1372 | 0.46 | Why? |
| Klebsiella pneumoniae | 1 | 2017 | 658 | 0.45 | Why? |
| Streptococcus agalactiae | 3 | 2018 | 194 | 0.45 | Why? |
| Canada | 30 | 2021 | 6018 | 0.44 | Why? |
| Serogroup | 5 | 2019 | 510 | 0.41 | Why? |
| Bacterial Load | 3 | 2018 | 179 | 0.38 | Why? |
| Pneumococcal Vaccines | 3 | 2019 | 571 | 0.36 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.32 | Why? |
| Seasons | 8 | 2019 | 4071 | 0.32 | Why? |
| Anti-Bacterial Agents | 8 | 2018 | 10083 | 0.31 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.31 | Why? |
| Ritonavir | 1 | 2021 | 4212 | 0.30 | Why? |
| Carrier State | 2 | 2017 | 2100 | 0.29 | Why? |
| Diagnostic Tests, Routine | 1 | 2017 | 2643 | 0.29 | Why? |
| Severe Acute Respiratory Syndrome | 11 | 2017 | 12361 | 0.29 | Why? |
| Genetic Variation | 4 | 2021 | 3919 | 0.28 | Why? |
| Vancomycin | 2 | 2018 | 328 | 0.27 | Why? |
| Influenza A virus | 5 | 2019 | 2234 | 0.27 | Why? |
| Drug Resistance, Bacterial | 5 | 2018 | 1414 | 0.26 | Why? |
| Hospitals | 10 | 2020 | 11793 | 0.24 | Why? |
| Staphylococcal Infections | 3 | 2019 | 1099 | 0.23 | Why? |
| Enterobacteriaceae | 2 | 2018 | 395 | 0.22 | Why? |
| SARS Virus | 8 | 2007 | 13021 | 0.22 | Why? |
| Orthomyxoviridae | 2 | 2020 | 1168 | 0.22 | Why? |
| Hospitalization | 13 | 2021 | 54280 | 0.21 | Why? |
| Hospital Units | 2 | 2018 | 1017 | 0.21 | Why? |
| Milk, Human | 2 | 2020 | 956 | 0.21 | Why? |
| Quantum Dots | 1 | 2021 | 129 | 0.20 | Why? |
| Saliva | 6 | 2021 | 4679 | 0.20 | Why? |
| Pasteurization | 1 | 2020 | 102 | 0.20 | Why? |
| Bacterial Proteins | 4 | 2018 | 1318 | 0.20 | Why? |
| Luciferases | 1 | 2021 | 378 | 0.19 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 2 | 2019 | 711 | 0.19 | Why? |
| Milk | 1 | 2020 | 158 | 0.19 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.18 | Why? |
| Fimbriae, Bacterial | 1 | 2017 | 14 | 0.18 | Why? |
| Mutation Rate | 1 | 2021 | 382 | 0.18 | Why? |
| Rabies Vaccines | 1 | 2018 | 106 | 0.18 | Why? |
| Streptococcal Infections | 3 | 2018 | 255 | 0.17 | Why? |
| Mass Screening | 2 | 2021 | 8005 | 0.17 | Why? |
| Clostridium Infections | 2 | 2018 | 595 | 0.17 | Why? |
| Preservation, Biological | 1 | 2017 | 46 | 0.17 | Why? |
| Outpatients | 2 | 2021 | 3417 | 0.17 | Why? |
| Emergency Medical Services | 1 | 2014 | 3557 | 0.17 | Why? |
| Humans | 92 | 2021 | 930598 | 0.17 | Why? |
| Anti-Infective Agents, Local | 2 | 2016 | 520 | 0.17 | Why? |
| Enterococcus faecium | 1 | 2018 | 95 | 0.17 | Why? |
| Genomic Instability | 1 | 2017 | 80 | 0.17 | Why? |
| Rabies | 1 | 2018 | 113 | 0.17 | Why? |
| Hand Hygiene | 2 | 2018 | 1493 | 0.17 | Why? |
| Air Microbiology | 3 | 2020 | 1322 | 0.16 | Why? |
| Staphylococcus aureus | 2 | 2018 | 844 | 0.16 | Why? |
| Electrochemical Techniques | 1 | 2021 | 406 | 0.16 | Why? |
| Penicillins | 1 | 2018 | 132 | 0.16 | Why? |
| Infection Control | 12 | 2020 | 23131 | 0.16 | Why? |
| Dose-Response Relationship, Immunologic | 1 | 2018 | 593 | 0.16 | Why? |
| Environmental Microbiology | 2 | 2018 | 575 | 0.16 | Why? |
| Ventilation | 2 | 2021 | 1145 | 0.16 | Why? |
| Multigene Family | 1 | 2017 | 377 | 0.16 | Why? |
| beta-Lactam Resistance | 1 | 2017 | 150 | 0.15 | Why? |
| Anesthesia, Epidural | 1 | 2016 | 92 | 0.15 | Why? |
| Enterocolitis, Pseudomembranous | 1 | 2016 | 93 | 0.15 | Why? |
| Vaccine Potency | 1 | 2017 | 339 | 0.15 | Why? |
| Molecular Typing | 1 | 2017 | 280 | 0.15 | Why? |
| Personnel, Hospital | 2 | 2020 | 2273 | 0.15 | Why? |
| Community-Acquired Infections | 2 | 2019 | 2328 | 0.15 | Why? |
| Vancomycin Resistance | 2 | 2018 | 55 | 0.13 | Why? |
| Adenoviridae | 1 | 2020 | 1151 | 0.13 | Why? |
| Vaccination | 9 | 2020 | 19050 | 0.13 | Why? |
| Inpatients | 3 | 2019 | 5161 | 0.13 | Why? |
| Patients' Rooms | 1 | 2018 | 675 | 0.13 | Why? |
| Antigens, Viral | 2 | 2020 | 6298 | 0.13 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2015 | 8843 | 0.13 | Why? |
| Vaccines, Inactivated | 2 | 2018 | 1562 | 0.12 | Why? |
| Anesthesia, Obstetrical | 1 | 2016 | 230 | 0.12 | Why? |
| Female | 49 | 2021 | 380317 | 0.12 | Why? |
| Virion | 1 | 2021 | 1444 | 0.12 | Why? |
| Adult | 36 | 2021 | 244371 | 0.12 | Why? |
| Disease Outbreaks | 11 | 2019 | 27595 | 0.12 | Why? |
| Urinary Tract Infections | 1 | 2018 | 534 | 0.12 | Why? |
| Antiporters | 1 | 2011 | 11 | 0.12 | Why? |
| Fecal Microbiota Transplantation | 1 | 2016 | 372 | 0.11 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.11 | Why? |
| Middle Aged | 37 | 2021 | 270681 | 0.11 | Why? |
| Respiratory Tract Infections | 4 | 2018 | 6817 | 0.11 | Why? |
| Male | 45 | 2021 | 367725 | 0.11 | Why? |
| Anti-Infective Agents | 2 | 2019 | 1766 | 0.11 | Why? |
| Coronavirus Infections | 12 | 2021 | 253789 | 0.11 | Why? |
| Diarrhea | 2 | 2016 | 2743 | 0.11 | Why? |
| Drug Combinations | 1 | 2021 | 3852 | 0.11 | Why? |
| Aged, 80 and over | 22 | 2020 | 88759 | 0.11 | Why? |
| Immunoassay | 3 | 2021 | 4485 | 0.11 | Why? |
| Perinatal Care | 1 | 2017 | 576 | 0.11 | Why? |
| Leukocytes, Mononuclear | 1 | 2020 | 2115 | 0.10 | Why? |
| Microbial Sensitivity Tests | 5 | 2018 | 2886 | 0.10 | Why? |
| Aged | 32 | 2021 | 215776 | 0.10 | Why? |
| Gram-Positive Bacterial Infections | 2 | 2018 | 323 | 0.10 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.10 | Why? |
| Adolescent | 17 | 2021 | 86841 | 0.10 | Why? |
| Young Adult | 17 | 2021 | 93724 | 0.10 | Why? |
| Membrane Transport Proteins | 1 | 2011 | 152 | 0.10 | Why? |
| Population Surveillance | 5 | 2019 | 4967 | 0.10 | Why? |
| Dexamethasone | 1 | 2021 | 2055 | 0.10 | Why? |
| Health Personnel | 8 | 2021 | 29646 | 0.10 | Why? |
| Pilot Projects | 2 | 2018 | 5182 | 0.10 | Why? |
| Nasopharynx | 4 | 2021 | 10224 | 0.10 | Why? |
| Chlorhexidine | 1 | 2011 | 176 | 0.10 | Why? |
| Equipment Contamination | 1 | 2018 | 1308 | 0.10 | Why? |
| Communicable Disease Control | 4 | 2018 | 29620 | 0.10 | Why? |
| Nursing Homes | 3 | 2020 | 4155 | 0.10 | Why? |
| Real-Time Polymerase Chain Reaction | 5 | 2021 | 11367 | 0.10 | Why? |
| Specimen Handling | 4 | 2021 | 6190 | 0.09 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2019 | 2984 | 0.09 | Why? |
| Antibodies, Viral | 5 | 2021 | 51949 | 0.09 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.09 | Why? |
| Health Services Research | 2 | 2012 | 756 | 0.09 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.09 | Why? |
| Immunization Programs | 2 | 2018 | 2006 | 0.09 | Why? |
| Switzerland | 3 | 2021 | 2738 | 0.09 | Why? |
| Influenza B virus | 3 | 2019 | 815 | 0.09 | Why? |
| Enterococcus | 1 | 2008 | 73 | 0.09 | Why? |
| Serotyping | 2 | 2018 | 154 | 0.09 | Why? |
| Viral Load | 2 | 2020 | 15850 | 0.09 | Why? |
| Loneliness | 1 | 2020 | 1766 | 0.09 | Why? |
| Animal Technicians | 1 | 2006 | 11 | 0.09 | Why? |
| Hand Disinfection | 2 | 2016 | 1671 | 0.09 | Why? |
| Frail Elderly | 1 | 2017 | 1427 | 0.08 | Why? |
| Genome, Viral | 2 | 2021 | 13157 | 0.08 | Why? |
| Vaccines, Synthetic | 1 | 2020 | 3231 | 0.08 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.08 | Why? |
| Methicillin Resistance | 1 | 2006 | 77 | 0.08 | Why? |
| Gastroenteritis | 1 | 2012 | 489 | 0.08 | Why? |
| Double-Blind Method | 1 | 2018 | 5988 | 0.08 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.08 | Why? |
| Biosensing Techniques | 1 | 2021 | 2116 | 0.08 | Why? |
| Veterinarians | 1 | 2006 | 49 | 0.08 | Why? |
| Aerosols | 2 | 2021 | 5393 | 0.08 | Why? |
| Practice Guidelines as Topic | 2 | 2021 | 15421 | 0.08 | Why? |
| Hospitals, Teaching | 2 | 2019 | 1609 | 0.08 | Why? |
| Disease Management | 2 | 2021 | 6841 | 0.08 | Why? |
| Genomics | 1 | 2018 | 3118 | 0.07 | Why? |
| Occupational Diseases | 1 | 2021 | 2787 | 0.07 | Why? |
| Prospective Studies | 11 | 2020 | 43301 | 0.07 | Why? |
| Multilocus Sequence Typing | 2 | 2018 | 264 | 0.07 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.07 | Why? |
| Multivariate Analysis | 4 | 2021 | 5440 | 0.07 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.07 | Why? |
| Public Health Surveillance | 4 | 2019 | 3129 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 2 | 2021 | 10649 | 0.07 | Why? |
| Genome, Bacterial | 2 | 2018 | 446 | 0.07 | Why? |
| Transcriptome | 1 | 2017 | 3466 | 0.07 | Why? |
| Ofloxacin | 1 | 2003 | 23 | 0.07 | Why? |
| Influenza A Virus, H3N2 Subtype | 2 | 2019 | 572 | 0.07 | Why? |
| Methylprednisolone Hemisuccinate | 1 | 2003 | 20 | 0.07 | Why? |
| Diagnosis, Differential | 4 | 2007 | 7220 | 0.07 | Why? |
| Drug Resistance, Multiple, Bacterial | 1 | 2012 | 1115 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2021 | 6537 | 0.06 | Why? |
| Air Pressure | 1 | 2003 | 119 | 0.06 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.06 | Why? |
| Guideline Adherence | 2 | 2019 | 2309 | 0.06 | Why? |
| Macrolides | 1 | 2006 | 369 | 0.06 | Why? |
| Sepsis | 1 | 2020 | 3517 | 0.06 | Why? |
| RNA, Viral | 3 | 2020 | 32276 | 0.06 | Why? |
| Immunoglobulin G | 3 | 2021 | 21571 | 0.06 | Why? |
| Pregnancy Complications, Infectious | 2 | 2018 | 11559 | 0.06 | Why? |
| Regression Analysis | 2 | 2020 | 2484 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.06 | Why? |
| Bisoprolol | 1 | 2021 | 65 | 0.06 | Why? |
| Risk Assessment | 2 | 2019 | 25439 | 0.06 | Why? |
| Limit of Detection | 2 | 2020 | 2698 | 0.06 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 3832 | 0.05 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.05 | Why? |
| Nasal Cavity | 1 | 2006 | 909 | 0.05 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 7868 | 0.05 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.05 | Why? |
| Immunity, Herd | 2 | 2019 | 1011 | 0.05 | Why? |
| Risk Factors | 11 | 2021 | 71621 | 0.05 | Why? |
| Soaps | 2 | 2016 | 134 | 0.05 | Why? |
| Communicable Diseases, Emerging | 4 | 2018 | 2523 | 0.05 | Why? |
| History, 21st Century | 2 | 2018 | 1849 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2019 | 4927 | 0.05 | Why? |
| Immunization, Passive | 3 | 2021 | 10067 | 0.05 | Why? |
| Social Isolation | 1 | 2020 | 5932 | 0.05 | Why? |
| Electrodes | 1 | 2021 | 203 | 0.05 | Why? |
| Infant | 6 | 2019 | 30274 | 0.05 | Why? |
| Drug Resistance | 1 | 2003 | 395 | 0.05 | Why? |
| Guillain-Barre Syndrome | 1 | 2013 | 1495 | 0.05 | Why? |
| Odds Ratio | 3 | 2018 | 5861 | 0.05 | Why? |
| Internet | 1 | 2018 | 6204 | 0.05 | Why? |
| Travel | 1 | 2018 | 7220 | 0.05 | Why? |
| Base Sequence | 2 | 2021 | 3581 | 0.05 | Why? |
| Sampling Studies | 1 | 2020 | 386 | 0.05 | Why? |
| Pneumonia | 1 | 2019 | 5652 | 0.05 | Why? |
| Glucocorticoids | 2 | 2007 | 4431 | 0.05 | Why? |
| Case-Control Studies | 4 | 2019 | 17671 | 0.05 | Why? |
| Long-Term Care | 3 | 2021 | 2047 | 0.05 | Why? |
| Incidence | 6 | 2018 | 25622 | 0.05 | Why? |
| DNA, Ribosomal | 1 | 2018 | 112 | 0.05 | Why? |
| Virus Replication | 1 | 2020 | 14331 | 0.05 | Why? |
| Infant, Newborn | 5 | 2018 | 23105 | 0.05 | Why? |
| Phylogeny | 4 | 2021 | 13341 | 0.05 | Why? |
| Spores, Bacterial | 1 | 2018 | 45 | 0.05 | Why? |
| Infant, Very Low Birth Weight | 1 | 2018 | 62 | 0.05 | Why? |
| Hospitals, Urban | 1 | 2004 | 950 | 0.05 | Why? |
| Prevalence | 5 | 2020 | 25773 | 0.04 | Why? |
| Erythromycin | 1 | 2017 | 17 | 0.04 | Why? |
| Streptococcal Vaccines | 1 | 2017 | 31 | 0.04 | Why? |
| Diagnostic Techniques and Procedures | 1 | 2020 | 265 | 0.04 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.04 | Why? |
| Fetal Membranes, Premature Rupture | 1 | 2018 | 122 | 0.04 | Why? |
| Respiratory Insufficiency | 1 | 2019 | 7301 | 0.04 | Why? |
| Cardiotonic Agents | 1 | 2020 | 418 | 0.04 | Why? |
| Bites and Stings | 1 | 2018 | 91 | 0.04 | Why? |
| Freezing | 1 | 2017 | 106 | 0.04 | Why? |
| Child | 7 | 2019 | 70012 | 0.04 | Why? |
| Absenteeism | 1 | 2019 | 287 | 0.04 | Why? |
| Gene Expression Regulation, Bacterial | 1 | 2017 | 143 | 0.04 | Why? |
| Genotype | 2 | 2020 | 4697 | 0.04 | Why? |
| Vaccines, Conjugate | 1 | 2019 | 328 | 0.04 | Why? |
| Bacterial Toxins | 1 | 2018 | 185 | 0.04 | Why? |
| Forearm | 1 | 2016 | 52 | 0.04 | Why? |
| Antibodies, Neutralizing | 2 | 2021 | 25288 | 0.04 | Why? |
| Gels | 1 | 2016 | 111 | 0.04 | Why? |
| Surveys and Questionnaires | 3 | 2019 | 43792 | 0.04 | Why? |
| DNA, Viral | 2 | 2020 | 2521 | 0.04 | Why? |
| Tertiary Care Centers | 3 | 2019 | 8248 | 0.04 | Why? |
| Child, Preschool | 5 | 2019 | 36283 | 0.04 | Why? |
| Animals | 5 | 2020 | 78931 | 0.04 | Why? |
| Ribavirin | 1 | 2003 | 1182 | 0.04 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.04 | Why? |
| Health Facilities | 1 | 2004 | 1230 | 0.04 | Why? |
| Severity of Illness Index | 2 | 2021 | 48226 | 0.04 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2020 | 3607 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Drug Resistance, Microbial | 1 | 2019 | 419 | 0.04 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.04 | Why? |
| Adhesins, Bacterial | 1 | 2014 | 39 | 0.03 | Why? |
| Disease Reservoirs | 1 | 2003 | 1672 | 0.03 | Why? |
| Occupational Exposure | 2 | 2019 | 4742 | 0.03 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.03 | Why? |
| Cross-Sectional Studies | 5 | 2021 | 53120 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Infant, Premature | 1 | 2018 | 883 | 0.03 | Why? |
| Area Under Curve | 1 | 2020 | 2564 | 0.03 | Why? |
| Sex Characteristics | 1 | 2021 | 1120 | 0.03 | Why? |
| Zoonoses | 1 | 2007 | 3034 | 0.03 | Why? |
| Hemodynamics | 1 | 2021 | 1562 | 0.03 | Why? |
| Shock | 1 | 2020 | 1868 | 0.03 | Why? |
| Single-Blind Method | 1 | 2016 | 1283 | 0.03 | Why? |
| Socioeconomic Factors | 2 | 2021 | 8495 | 0.03 | Why? |
| Intensive Care Units, Neonatal | 1 | 2018 | 749 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.03 | Why? |
| Kinetics | 1 | 2020 | 3238 | 0.03 | Why? |
| Sequence Analysis, RNA | 1 | 2021 | 2290 | 0.03 | Why? |
| Nose | 1 | 2018 | 1093 | 0.03 | Why? |
| Virulence Factors | 1 | 2014 | 338 | 0.03 | Why? |
| Retrospective Studies | 6 | 2019 | 105322 | 0.03 | Why? |
| Logistic Models | 3 | 2017 | 9089 | 0.03 | Why? |
| Survival Rate | 2 | 2019 | 9206 | 0.03 | Why? |
| Ethanol | 1 | 2016 | 533 | 0.03 | Why? |
| Pregnancy | 3 | 2018 | 23879 | 0.03 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.03 | Why? |
| Neoplasms | 1 | 2019 | 17251 | 0.03 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.03 | Why? |
| Immunization Schedule | 1 | 2018 | 1305 | 0.03 | Why? |
| Anesthesiologists | 1 | 2016 | 614 | 0.03 | Why? |
| Air Pollution, Indoor | 1 | 2019 | 816 | 0.03 | Why? |
| Patient Positioning | 1 | 2021 | 1505 | 0.03 | Why? |
| Quebec | 1 | 2012 | 498 | 0.03 | Why? |
| Comorbidity | 3 | 2019 | 34796 | 0.02 | Why? |
| Visitors to Patients | 1 | 2016 | 671 | 0.02 | Why? |
| Smartphone | 1 | 2021 | 1840 | 0.02 | Why? |
| Confidence Intervals | 1 | 2012 | 744 | 0.02 | Why? |
| Administration, Oral | 1 | 2016 | 2340 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2020 | 3239 | 0.02 | Why? |
| Bacterial Infections | 1 | 2003 | 2229 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Cesarean Section | 1 | 2018 | 2089 | 0.02 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.02 | Why? |
| Time Factors | 3 | 2018 | 31397 | 0.02 | Why? |
| Health Surveys | 1 | 2019 | 2841 | 0.02 | Why? |
| Latex Fixation Tests | 1 | 2006 | 8 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.02 | Why? |
| Survivors | 1 | 2020 | 2619 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.02 | Why? |
| Penicillin-Binding Proteins | 1 | 2006 | 31 | 0.02 | Why? |
| HEK293 Cells | 1 | 2021 | 8394 | 0.02 | Why? |
| Hospitals, Community | 1 | 2012 | 475 | 0.02 | Why? |
| Follow-Up Studies | 2 | 2019 | 17020 | 0.02 | Why? |
| Emergency Service, Hospital | 1 | 2012 | 14232 | 0.02 | Why? |
| Neutralization Tests | 1 | 2020 | 6698 | 0.02 | Why? |
| Phenotype | 1 | 2018 | 4037 | 0.02 | Why? |
| Recurrence | 1 | 2016 | 3675 | 0.02 | Why? |
| Medical Staff, Hospital | 1 | 2016 | 1258 | 0.02 | Why? |
| Laboratories | 1 | 2019 | 2858 | 0.02 | Why? |
| Microbiota | 1 | 2016 | 1240 | 0.02 | Why? |
| Acute Disease | 1 | 2019 | 6029 | 0.02 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Infectious Disease Incubation Period | 1 | 2013 | 1033 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Drug Utilization | 1 | 2011 | 619 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 13720 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Public Health | 2 | 2021 | 16359 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2019 | 23402 | 0.02 | Why? |
| Chronology as Topic | 1 | 2003 | 13 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2017 | 3493 | 0.02 | Why? |
| Aging | 1 | 2020 | 3581 | 0.02 | Why? |
| Coronavirus | 1 | 2013 | 18339 | 0.02 | Why? |
| Patient Isolation | 1 | 2017 | 3182 | 0.02 | Why? |
| Chiroptera | 1 | 2018 | 3530 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.02 | Why? |
| Disease Transmission, Infectious | 2 | 2019 | 9044 | 0.02 | Why? |
| Nursing Staff, Hospital | 1 | 2016 | 1554 | 0.02 | Why? |
| Protective Clothing | 1 | 2006 | 468 | 0.01 | Why? |
| Saudi Arabia | 1 | 2013 | 4423 | 0.01 | Why? |
| Nurses | 1 | 2018 | 2285 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Prognosis | 2 | 2019 | 32490 | 0.01 | Why? |
| Pedigree | 1 | 2003 | 502 | 0.01 | Why? |
| Clinical Trials as Topic | 1 | 2020 | 7330 | 0.01 | Why? |
| Treatment Failure | 1 | 2006 | 2106 | 0.01 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.01 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.01 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.01 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.01 | Why? |
| Hospitals, University | 1 | 2012 | 4173 | 0.01 | Why? |
| Physicians | 1 | 2018 | 4214 | 0.01 | Why? |
| Coinfection | 1 | 2018 | 6820 | 0.01 | Why? |
| Cluster Analysis | 1 | 2006 | 3001 | 0.01 | Why? |
| Family Health | 1 | 2003 | 731 | 0.01 | Why? |
| Triage | 1 | 2017 | 7151 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2013 | 9706 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2021 | 12447 | 0.01 | Why? |
| Early Diagnosis | 1 | 2006 | 2443 | 0.01 | Why? |
| Interviews as Topic | 1 | 2006 | 1952 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Renal Dialysis | 1 | 2013 | 4358 | 0.01 | Why? |
| Taiwan | 1 | 2004 | 2556 | 0.01 | Why? |
| Radiography | 1 | 2003 | 1576 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Personnel Staffing and Scheduling | 1 | 2003 | 1578 | 0.01 | Why? |
| Environmental Exposure | 1 | 2003 | 1558 | 0.01 | Why? |
| Age Factors | 1 | 2012 | 21039 | 0.01 | Why? |
| Dyspnea | 1 | 2003 | 3847 | 0.01 | Why? |
| Cough | 1 | 2003 | 4891 | 0.01 | Why? |
| Fever | 1 | 2003 | 7795 | 0.00 | Why? |
| Disease Progression | 1 | 2003 | 13580 | 0.00 | Why? |
| Masks | 1 | 2006 | 8528 | 0.00 | Why? |
| Contact Tracing | 1 | 2003 | 8448 | 0.00 | Why? |
| United States | 1 | 2003 | 46150 | 0.00 | Why? |
| Lung | 1 | 2003 | 31049 | 0.00 | Why? |